4.3 Article

In vivo comparison of a polymer-free Biolimus A9-eluting stent with a biodegradable polymer-based Biolimus A9 eluting stent and a bare metal stent in balloon denuded and radiated hypercholesterolemic rabbit iliac arteries

Journal

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS
Volume 80, Issue 3, Pages 429-436

Publisher

WILEY
DOI: 10.1002/ccd.23407

Keywords

drug-eluting stent; polymer; biolimus A9; neointima

Funding

  1. Biotronik
  2. Medtronic
  3. Boston Scientific
  4. Medicines Co.
  5. GlaxoSmithKline
  6. Schering-Plough
  7. Sanofi-Aventis
  8. 3F Therapeutics
  9. Abbott Vascular
  10. Amaranth Medical, Inc.
  11. Apnex Medical
  12. Ardian, Inc.
  13. Atrium Medical Corporation
  14. CardioDex, Ltd.
  15. CardioKinetix, Inc.
  16. CorAssist Cardiovascular, Ltd.
  17. Cordis Corporation
  18. Devax, Inc.
  19. ev3
  20. Gardia Medical, Ltd.
  21. HemCon
  22. Lutonix, Inc.
  23. Medtronic Vascular
  24. Meril Life Sciences Pvt, Ltd.
  25. Microvention, Inc.
  26. Novartis Pharmaceuticals Corporation
  27. NovoStent Corporation
  28. Oregon Medical Laser Center
  29. Prescient Medical, Inc.
  30. Relisys Medical Devices Limited
  31. Vascular Therapies, LLC
  32. Xtent, Inc.

Ask authors/readers for more resources

Objectives: To evaluate the effect of a polymer-free Biolimus A9-eluting stent [BioFreedom (TM) (BF)], compared with that of a biodegradable polymer-based Biolimus A9-eluting stent [BioMatrix Flex (TM) (BMF)] and a bare metal stent (BMS) in balloon denuded and radiated hypercholesterolemic rabbit iliac arteries. Methods: Rabbits were fed with 1% cholesterol diet (n = 14) for 14 days, both iliac arteries were balloon denuded and radiated, and then rabbits were switched to 0.15% cholesterol diet. After 4 weeks, BF (n = 8), BMF (n = 8), and BMS (n = 8) were deployed in denuded and radiated areas. Four weeks later animals were euthanized, arterial segments were processed for morphometry. Results: The neointimal area in vessels implanted with BF stents was significantly less than that seen in vessels implanted with BMS (0.90 mm2 +/- 0.14 vs. 1.29 mm2 +/- 0.23, P <0.01). Percent fibrin and fibrin score were higher with BMF stents compared to BMS (P <0.03 and <0.04) and giant cell number was significantly higher with both BMF and BF stents (P < 0.01 for both). Percent endothelialization was significantly higher and % uncovered struts were lower with BMS compared to either BMF or BF stents (P < 0.05 for both). Conclusion: This study demonstrates that compared to BMS, BF stents significantly decreased neointimal hyperplasia. (c) 2011 Wiley Periodicals, Inc.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available